The Development of a Guidance of Combined HA and ESWT for Non-calcific Rotator Cuff Lesions Without Complete Tear

NCT ID: NCT05034757

Last Updated: 2021-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

138 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-31

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The rotator cuff lesions are common disorders of the shoulder joint and mainly caused by intrinsic degeneration and outlet impingement. The symptoms include pain, discomfort, weakness, range of motion limitation, and impingement. The initial treatment of rotator cuff lesions are non-surgical especially for non-full thickness tearing and include rehabilitation and medications given orally, topically, or parenterally. Although many patients with rotator cuff lesions or subacromial pain are treated with, and will respond to non- surgical treatment alone, surgical intervention with subacromial decompression and rotator cuff repair is often used as an early treatment choice or in recalcitrant cases. The indications for surgery are persistent and severe shoulder pain combined with functional restrictions that are resistant to conservative measures. However, the effectiveness of this procedure is still elusive. Some studies have compared decompression plus subacromial bursectomy with bursectomy alone and reported no significant difference in clinical outcome between groups.

In addition, arthroscopic subacromial decompression for shouled impingement was currently challenged because some high-quality prospective studies including that from Oxford university showed similar outcomes between surgical and non-surgical treatment. Therefore more efficient non-surgical treatments were needed for the rotator cuff lesions without complete tear.

The investigators have successfully treated non- calcific rotator cuff lesions without complete tearing with hyaluronate and published our data in J Shoulder Elbow surgery. Jun 19:557-63, 2010.

In the Phase III study, the investigators will perform three subacromial hyaluronate injections and zero to two sessions of extracorporeal shock wave therapy (ESWT) for these patients. The investigators hypothesize that through the actions of anti-inflammation, neovascularization and temporary cell permeability increment, a combined therapy of HA and ESWT may offer better therapeutic effects on the non-calcific rotator cuff lesion without complete tearing. The investigators will evaluate the treatment effects with Constant score and VAS scale and also check the changes or expressions of cytokines, growth factors, functional proteins, from the peripheral blood.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The rotator cuff lesions are common disorders of the shoulder joint and mainly caused by intrinsic degeneration and outlet impingement. The symptoms include pain, discomfort, weakness, range of motion limitation, and impingement. The initial treatment of rotator cuff lesions are non-surgical especially for non-full thickness tearing and include rehabilitation and medications given orally, topically, or parenterally.

Although many patients with rotator cuff lesions or subacromial pain are treated with, and will respond to non- surgical treatment alone, surgical intervention with subacromial decompression and rotator cuff repair is often used as an early treatment choice or in recalcitrant cases. The indications for surgery are persistent and severe subacromial shoulder pain combined with functional restrictions that are resistant to conservative measures. However, the effectiveness and necessity of this procedure is still elusive. Some studies have compare decompression plus subacromial bursectomy with bursectomy alone and reported no significant difference in clinical outcome between groups.

In addition, arthroscopic subacromial decompression for shouled impingement was currently challenged because some high-quality prospective studies including that from Oxford university showed similar outcomes between surgical and non-surgical treatment. Therefore more efficient non-surgical treatments were needed for the rotator cuff lesions without complete tear.

The investigators have successfully treated non-calcific rotator cuff lesions without complete with hyaluronate and published our data in J Shoulder Elbow Surg. Jun 19:557-63,2010.

In the phase III study, the investigators will perform three subacromial hyaluronate injections and zero to two sessions of extracorporeal therapy (ESWT). The investigators hypothesize that through the actions of anti-inflammation, neovascularization and temporary cell permeability increment of ESWT, a combined therapy of HA and ESWT may offer better therapeutic effects on the non-calcific rotator cuff lesion without complete tearing. The investigators will evaluate the treatment effects with constant score and VAS, and also check the changesor expressions of cytokines, growth factors, functional protein, from the peripheral blood.

1. Acceptance criteria:

The randomized, double-blind, placebo-controlled clinical study will involve 69 or more patients who have non-calcific rotator cuff lesions without complete tear. The inclusion criteria are (1) patients who have pain around the shoulder, a positive impingement sign, and a positive imaging diagnosis of rotator non-calcific cuff pathology without complete tear; (2) patients who do not respond to conservative therapy or rehabilitation for at least 3 months; and (3) patients age between 35 and 80 years, who sign the informed consent form. The investigators will exclude patients who have rheumatic diseases, glenohumeral osteoarthritis, full-thickness cuff tears, fractures, infections, or tumors; those who have received a subacromial injection within 3 weeks; and those who are pregnant or want to become pregnant.

The sample size is calculated under the expectation of an improvement in the Constant score of 10 points, with an SD of 12 points in each group, and a power value of 0.8. For this study design, the minimal number of patients required in each group is 23, by use of an independent-samples t test. The intent-to-treat population is a fully randomized group of patients who have a baseline value (Constant score and VAS before treatment). The imaging diagnosis of a rotator cuff lesion is made by a musculoskeletal radiologist who has considerable experience in interpreting both magnetic resonance imaging (MRI) and sonographic results for shoulders. On the sonogram, hypoechoic thickening of the rotator cuff indicates tendinosis. Focal thinning or focal hypoechoic areas of discontinuity in the rotator cuff are suggestive of partial-thickness tearing. In cases of the hypoechoic gap extending through the entire rotator cuff, tendon retraction, or the absence of a visible rotator cuff, a full thickness tear is assumed to be present. On MRI, rotator cuff tendinosis is characterized by increased intratendinous signal intensity on T2-weighted images without tendon disruption. Partial-thickness tearing is characterized by the presence of focal hyperintense fluid or a fluid-like signal intensity that extended into the tendon on the T2-weighted images. A full thickness tear is diagnosed by the extension of hyperintense fluid or fluid-like signal intensity through the entire thickness of the interrupted rotator cuff tendon on T2-weighted images.
2. Experiment design and method Patients are then randomly into three groups and every patient receives three injections of HA along with ESWT treatment based on statistical randomization. For ESWT of the shoulder the patient will receive Storz Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder. Treatments are performed on an outpatient basis. The areas of treatment (2 points) near the supraspinatus insertion is focused with a control guide on the machine, and surgical lubricant is placed on the skin in contact with the shockwave tube. The sham treatment entails use of the same device in which the shockwave generator is disconnected. The patients' vital signs and local discomfort are monitored throughout the course of treatment. The treated area is inspected for local swelling, ecchymosis, or hematoma immediately after the treatment. Our primary endpoint is the Constant Score improvement by 10 points and the treatment success is followed up to 1 year. The Constant score pain score and the range of shoulder motion are measured. Another kind of pain and pain that requires surgery is classified as a failure case, which is the secondary endpoint.
3. Rehabilitation including gentle flexion, abduction, internal rotation and external rotation exercises, pendulum exercises, and resistant exercises will be instructed and continued during the study period.

Patients will have a pain medication-free interval 2 days prior to each evaluation. After treatment and during follow-up, patients will be restricted to the use of a 750mg of acetaminophen per day for pain, in order to fascilitate usage and comparison of the medications among the patients. Follow-up examinations with range of motion, VAS and Constant score are performed independently by one of the coauthors, who is blinded to patient treatment status during the treatment course and at 1week, 1month, 3months, 6 months, and 12 months after treatment. Peripheral blood (10cc) will be collected during the treatment course and 1 week, 1 month and 3 month after treatment and shoulder MRI will be checked 12 months after treatment. Patients who have persistent shoulder discomfort may be advised to undergo surgical intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rotator Cuff Lesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyaluronate

HA injection

Group Type EXPERIMENTAL

HA only

Intervention Type OTHER

HA injection only

HA + ESWT

HA + ESWT

Group Type EXPERIMENTAL

ESWT once

Intervention Type OTHER

ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder

ESWT twice

Intervention Type OTHER

ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HA only

HA injection only

Intervention Type OTHER

ESWT once

ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder

Intervention Type OTHER

ESWT twice

ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pain around the shoulder, a positive impingement sign
2. Diagnosis of non-calcific rotator cuff pathology without complete tear
3. Do not respond to conservative therapy or rehabilitation for at least 3 months

Exclusion Criteria

1. Rheumatic diseases
2. Glenohumeral osteoarthritis
3. Full-thickness cuff tears
4. Fractures
5. Infections
6. Tumors
7. Received a subacromial injection within 3 weeks
8. Pregnant or want to become pregnant.
Minimum Eligible Age

35 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chang Gung Memorial Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jih-Yang Ko

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jih-Yang Ko, MD

Role: PRINCIPAL_INVESTIGATOR

Chang Gung Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jih-Yang Ko, MD

Role: CONTACT

886-7-731-7123

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jih-Yang Ko, MD

Role: primary

886-7-731-7123 ext. 8003

References

Explore related publications, articles, or registry entries linked to this study.

Ko JY, Huang CC, Huang PH, Chen JW, Liao CY, Kuo SJ. Effects of supplementing extracorporeal shockwave therapy to hyaluronic acid injection among patients with rotator cuff lesions without complete tear: a prospective double-blinded randomized study. Int J Surg. 2024 Dec 1;110(12):7421-7433. doi: 10.1097/JS9.0000000000002063.

Reference Type DERIVED
PMID: 39172722 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201900290B0A3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.